Pharma forum 2022

Industry event

Pharma forum 2022

    • - BST

After the success of last year's virtual event, we're excited to announce a return to an in-person occasion this year at our London office. 

Join us for a day exploring the legal and commercial issues that matter most to pharmaceutical and biologics companies across the UK and Europe.  

We have broadly split the day's content into two parts. Over the course of the morning, we will lead with the hot issues around intellectual property in pharma.  The afternoon will see discussion focusing on broader commercial and regulatory issues.  Depending on your areas of interest, please select from the RSVP whether you are interested in attending some or all of the day.

In addition to our specialist panel of speakers and contributors, we are also delighted to announce that Hannah Kuchler, global pharmaceuticals correspondent for the FT will be co-chairing the day alongside our Head of International Life Sciences, Alison Dennis.  Hannah will of course be contributing her unique insights throughout the day and we are delighted to say, she has also agreed to deliver a thought-provoking and interesting keynote after lunch.

We look forward to welcoming you to our offices for this not to be missed event on Thursday 22 September.

Event details

Address

DX 41 London
5 New Street Square
London EC4A 3TW
UK

Get directions

Programme

09:00 Registration
09:30 Welcome
09:45 Compulsory licensing in Europe – quick but not easy; what are the alternatives?
10:15 Rare diseases: exclusivity protection and its limits for therapeutic products in this area
11:00 Coffee break
11:15 The Unified Patent Court and Unitary Patent: discussing the big strategic questions
12:00 Preparing your company for an exit
12:30 Lunch
13:30 Welcome back
13:35 Keynote speech by Hannah Kuchler, global pharmaceuticals correspondent, Financial Times
View full programme Hide full programme

Guest speakers

Elizabeth Crooks
Kilburn & Strode - Partner

Elizabeth is involved in all areas of patent protection, including working closely with companies to identify inventions, drafting patent applications and prosecuting them to grant. She has extensive experience of prosecution in patent offices worldwide, including in particular, Europe, Japan, China and South Korea.

Elizabeth works with her clients to propose patent protection strategies, including invention capture and patent portfolio management. She also provides advice on third party patents/ applications including patent landscaping and providing infringement and validity opinions.

She has particular experience in opposition and appeal proceedings before the European Patent Office.

Elizabeth works in all areas of chemistry including pharmaceutical chemistry. She has particular experience in working in the area of industrial chemistry, particularly on low Global Warming Potential fluorocarbons, materials for films and coatings, polymers, catalysts, solvents, refrigerants, foam blowing agents, security markings, propellants and large scale synthetic processes.

Elizabeth works for a variety of companies, from universities and spin-out companies through to blue-chip multinational corporations.

More Less

Hannah Kuchler
Financial Times - Global pharmaceuticals correspondent

Hannah Kuchler is the global pharmaceuticals correspondent for the Financial Times, leading the international business newspaper’s coverage of the life sciences industry. She has reported on the Covid-19 pandemic, receiving an honourable mention at the Society for Advanced Business Editing and Writing awards for a feature she led on the Pfizer vaccine. 

In the US, Kuchler collaborated with PBS Frontline on a documentary about the opioids crisis, which was nominated for an Emmy and won a Loeb award. She has worked for the FT for twelve years in London, Hong Kong, New York, and San Francisco.

More Less

Register for this event

Click here to register your interest

If you have any questions please use the following details:

Related events

29 September

14:00 - 15:00

Webinar

The EU Whistleblowing Directive - 2022 update

More